Clinical trials
Metastatic Adenocarcinoma clinical trials
Below are recruiting metastatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT07327229RecruitingPhase 1/Phase 2
Study of ATG-022 plus pembrolizumab for stomach or GEJ cancer
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
Hefei, AnhuiAges 18 years+ - NCT06675136RecruitingPhase 1
Nab-paclitaxel PIPAC with paclitaxel and ramucirumab for stomach cancer spread to belly lining
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Duarte, CaliforniaAges 18 years+ - NCT06921837RecruitingPhase 1/Phase 2
BDC-4182 for advanced gastric or gastroesophageal cancer
This trial tests a new drug called BDC-4182 for advanced gastric or gastroesophageal cancer. It is for people who have already tried standard treatments and may target a protein called Claudin 18 on some cancer cells.
Darlinghurst, New South WalesAges 18 years+ - NCT06843551RecruitingPhase 2
Testing a new immunotherapy combo for advanced pancreatic cancer
This trial is testing two immunotherapy drugs (balstilimab and botensilimab) to see if they can shrink tumors in people with advanced pancreatic cancer that has worsened after at least one prior treatment. If you have microsatellite stable (MSS) disease, you may be eligible.
Miami, FloridaAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT06743867RecruitingPhase 1
Chemotherapy mist for cancer spread in the belly
This trial tests a new way to give chemotherapy directly into the belly as a fine mist (called PIPAC) for people whose cancer has spread there. The goal is to see if it’s safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07664891Recruiting
Metabolism and surroundings in pancreatic cancer
This study looks at how the metabolism of pancreatic cancer cells affects their surroundings. It uses a biopsy (removing a small sample of tissue from a tumor in the pancreas, liver, or lung) to learn more about the cancer and guide treatment.
MarseilleAges 18 years+ - NCT07377045RecruitingPhase 1
New combo for advanced pancreatic cancer
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT07624487RecruitingPhase 2
Aumolertinib and chemotherapy for EGFR L858R lung cancer
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
New Taipei CityAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Aurora, ColoradoAges 18 years+ - NCT06773312RecruitingPhase 1
Study of BC001 plus Sintilimab and XELOX for advanced stomach cancer
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT05472948RecruitingPhase 2
Testing surufatinib plus immunotherapy with capecitabine for bowel cancer
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18–70 - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Scottsdale, ArizonaAges 18 years+ - NCT07344220Enrolling by invitationPhase 2
Maintenance therapy study for stable metastatic pancreatic cancer
This trial tests a new drug, DZ-002, as maintenance therapy for people with metastatic pancreatic cancer whose disease has not worsened after at least 4 months of first-line chemotherapy. The goal is to help keep the cancer under control with fewer side effects.
Newport Beach, CaliforniaAges 18 years+ - NCT06051851RecruitingPhase 2
Study of penpulimab, anlotinib, and chemo for advanced pancreatic cancer
This trial tests a combination of immunotherapy (penpulimab), a targeted therapy (anlotinib), and two chemotherapy drugs (nab-paclitaxel and gemcitabine) as a first treatment for pancreatic cancer that has spread. It aims to see if this new combination works better than standard care.
Nanjing, JiangsuAges 18 years+ - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT04339218RecruitingPhase 3
Cryoablation plus pembrolizumab and chemotherapy for lung cancer spread
This trial studies whether freezing a small number of lung cancer spots (cryoablation) alongside standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes in people with metastatic lung adenocarcinoma. It’s meant for people who have measurable tumors that can be safely targeted with the freezing treatment.
Bordeaux, GirondeAges 18 years+ - NCT05821556RecruitingPhase 2
New drug combo test for untreated metastatic pancreatic cancer
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Naples, ItalyAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70
Hear when a new Metastatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic adenocarcinoma?
- Yes. Clin2 currently lists 237 recruiting metastatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Prostate Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Gastric Cancer Adenocarcinoma Metastatic
- Metastatic Esophageal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.